
## Site map **ECTU + Clinical Cancer Research Group (CCRG)**



# **Realized structures for phase I+I/II clinical trials (CTs)**


- 6 beds (3 outpt care in ECTU, 3 inpt beds ward 'Holthusen')
- SN support, study coordination, monitoring, CTx-management, pharmacology, TBD: all integrated in new ECTU unit
- Medical equipment all available (monitors, infusion pumps, ECG, emergency equipment)
- CT-specific equipment in place (centrifuges, refrigerators, study medication storage room, monitoring + study audit capacities)
- Combined organization of phase I/II + Leucapheresis (LP) + CCR-Group to personnel-efficient unit
- Proximity to leukemia ward (24h-physician support)
- Central location + easy access to intensive care unit  $\rightarrow$  Central unit for all oncology-active departments for

## proficient ECTU performance

## **Staffing ECTU/LP/Med I team**

**Present personnel structure** ECTU/LP/Med I:

- Senior physicians
- GCP-approved physicians
- Study Nurses
- TBD
- Study coordination
- Pharmacists
- (CTx-management / study support) • MTA
- Biometry
- PhD position (Pharmacist)
- Secretary



# **CCCF - Early Clinical Trial Unit (ECTU)** M. Möller, L. Illert, A. Krohn, C. Kiote-Schmidt, U. Kohlweyer, F. Haug, M. Falahen, C. Messner, J. Meisenzahl, D. Jakobs, M. Linder, S. Kappes, I. Surlan, M. Höfflin, H. Fricker, H. Reinhardt, S. Kaiser, M. Szymaniak-Vits, P. Otte, H. Schall, J. Urban, S. Demmig, S. Wenske, R. Lohmüller, R. Wäsch, R. Bredenkamp, J. Duyster, M. Engelhardt


Total study team Med 1:

15

40

#### **Clinical Trials University Medical Center** Freiburg (UKF)

#### # of ongoing CTs<sub>CCCF/UKF</sub>



## **Currently performed phase I/II CTs**<sub>CCCF/UKF</sub>

- IIT initiated by CCCF


Clinic	UKF
Hematology & Oncology, Med. I	19
Gastroenterology, Med. II	2
ZKJ	4
Urology	1
Neurology	1
Total	27

## **Early Clinical Trials at Department of** Hematology & Oncology

### # of CTs, included pts and pt-#/CT at Med $I_{2014}$

	Phase I, I/II	Phase II	Phase III	Other	Σ
# of CTs	19	35	46	19	119
# of pts	78	256	226	1018	1578
Pt-# / CT	4.2	7.3	4.9	53.6	13.3





## **Opportunities and prospects of ECTU**

- •As central research and investigations for UKF
- personnel for outpts and inpts

- Head of Trial Unit: Prof. Dr. M. Engelhardt
- Section Haematology: FOA Dr. L. Illert
- Section Oncology: A. Krohn

\* Industry cooperations: Novartis: OTM certification 8/2014 Roche: in preparation Bayer: in dialogue Preferred partner Quintiles since 10/2013 Preferred partner, preclinical collaborations: Oncotest; Prof. Fiebig / Dr. J. Schüler



#### **Trial discussion and acceptance modus**

unit, the ECTU allows translational further improves oncology

• Logistic and structural requirements for expertise performance of early CTs with GCP-approved

• Enables all oncology-active departments within interdisciplinary platform to perform phase I+I/II CTs • Fulfills all requirements for phase I + I/II CTs, also as

```
a proficient partner for pharmaceutical companies*
```

• Is integral part of the CCCF and directed in close collaboration with CCCF associated members